TOKYO--(BUSINESS WIRE)--Mirailab Bioscience Inc. (Head office: Chuo-ku, Tokyo, CEO: Megumi Tanaka) has obtained patent rights in China for "Food or beverage for babies and infants, method for improving intestinal environment of baby or infant, and method for enhancing immunity of baby or infant" which had been pending a patent (PCT) international application.

Patent Summary

Application No. : PCT/JP2020/004947 (Chinese Patent 113438896)

Name of invention (in English): Food or beverage for babies and infants, method for improving intestinal environment of baby or infant, and method for enhancing immunity of baby or infant

It is a patent for a method for improving the immature intestinal environment of baby or infant and a method for enhancing immunity of baby or infant, and is characterized by the inclusion of nicotinamide mononucleotide (NMN) in food or beverage for babies and infants.
Compared to infants raised on breast milk, infants raised on conventional milk powder tend to be more susceptible to infectious diseases due to insufficient immunity or disorder of the intestinal environment caused by the imbalance between bifidobacteria, which are beneficial bacteria, and E. coli, which are harmful bacteria in the intestinal flora, so the development of infant foods and beverages that have enhanced intestinal environment improvement and immunostimulatory capacity (infection defense function) has been awaited. Therefore, the present invention develops an infant food and beverage containing NMN, and provides an infant food and beverage that can improve the intestinal environment of infants and strengthen their immunity, a method for improving the intestinal environment of infants and a method for enhancing immunity of infants.
In addition, the present invention is expected to be effective in babies and infants who mainly consume infant milk powder, infants whose intestinal environment has disordered, and infants with low immunity.

About NMN

NMN is a component that is naturally produced in the body using materials such as vitamin B3, and is an indispensable substance for the activity of cells in the body. It is also believed that the decrease in NMN production in the body with age is one of the factors that exacerbates various age-related diseases (lifestyle-related diseases, cancer, dementia, etc.). In recent years, there has been an acceleration in the application of the excellent properties of NMN, such as anti-aging, treatment of neurodegenerative diseases, and protection of the heart, to functional food ingredients, healthcare products, pharmaceuticals and pharmaceutical intermediates.

Examples

Evaluation of the effect of promoting immunoglobulin M (IgM) production
In order to confirm the change in IgM concentration in the blood due to the intake of infant food and drink containing nicotinamide mononucleotide, a test was conducted on male and female infants aged 1.8~6.5 years. IgM is a type of antibody that is first produced from immune cells called B cells when infected with bacteria or viruses.
23 infants were divided into two groups, one group (11 infants) was fed powdered milk alone, and the other group (12 infants) was fed powdered milk with nicotinamide mononucleotide (compound (+)) once a day in the morning for approximately 30 days, and the IgM concentration (mg/dl) in the blood in each group was measured before lactation and after about 30 days of feeding. The average value was determined (except for subjects with IgM concentrations less than 120 mg/dl in their blood before breastfeeding). The group that was fed powdered milk supplemented with nicotinamide mononucleotide was fed powdered milk containing 100 mg of nicotinamide mononucleotide per day.
As shown in the figure, the IgM concentration had a greater increase from before to after breastfeeding in the group that was fed powdered milk supplemented with nicotinamide mononucleotide compared to the group that was fed powdered milk alone. From these results, it was found that the infant food and drink of the present invention is effective in increasing the IgM concentration in the blood.

About Mirailab Bioscience Inc.

We are a leading company for NMN that starts selling NMN supplements in 2015, first in the world (1). With the aim of realizing scientifically based "productive aging" all over the world, we will continue to contribute to the improvement of quality of life through the expansion of the mail-order series for analysis of health levels that enables quantification of the effects of NMN, "MiRMes" Mirailab Remote Medical Check Series (2) and the supply of NMN supplements, NMN infusion research reagent raw materials, NMN-containing cosmetics, etc. (3).

(1) https://www.atpress.ne.jp/news/59540
(2) https://prtimes.jp/main/html/rd/p/000000015.000103030.html
(3) https://mirai-lab.jpn.com/pages/history